Patents by Inventor Mark David Wogulis

Mark David Wogulis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GH61 VARIANTS AND POLYNUCLEOTIDES ENCODING SAME
    Publication number: 20240110169
    Abstract: The present invention relates to GH61 polypeptide variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Application
    Filed: November 30, 2023
    Publication date: April 4, 2024
    Applicants: Novozymes A/S, Novozymes, Inc.
    Inventors: Janine Lin, Doreen Bohan, Michelle Maranta, Leslie Beresford, Michael Lamsa, Matt Sweeney, Mark David Wogulis, Elizabeth Znameroski, Frank Winther Rasmussen
  • GH61 polypeptide variants and polynucleotides encoding same
    Patent number: 11891637
    Abstract: The present invention relates to GH61 polypeptide variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Grant
    Filed: April 6, 2022
    Date of Patent: February 6, 2024
    Assignee: Novozymes, Inc.
    Inventors: Janine Lin, Doreen Bohan, Michelle Maranta, Leslie Beresford, Michael Lamsa, Matt Sweeney, Mark David Wogulis, Elizabeth Znameroski, Frank Winther Rasmussen
  • GH61 Polypeptide Variants and Polynucleotides Encoding Same
    Publication number: 20220307002
    Abstract: The present invention relates to GH61 polypeptide variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Application
    Filed: April 6, 2022
    Publication date: September 29, 2022
    Applicant: Novozymes, Inc.
    Inventors: Janine Lin, Doreen Bohan, Michelle Maranta, Leslie DeMars, Michael Lamsa, Matt Sweeny, Mark David Wogulis, Elizabeth Znameroski, Frank Winther Rasmussen
  • Xylanase variants and polynucleotides encoding same
    Patent number: 10370682
    Abstract: The present invention relates to xylanase variants, comprising an alteration at least at one position corresponding to position 87 of the polypeptide of SEQ ID NO: 3, wherein the variant has xylanase activity and has increased xylanase inhibitor tolerance compared to the xylanase of SEQ ID NO: 3; and i) wherein the variant has at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%, but less than 100% sequence identity to the polypeptide of SEQ ID NO: 3; or ii) wherein the number of alterations is 1-20, e.g., 1-10 such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 alterations. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: August 6, 2019
    Assignee: NOVOZYMES A/S
    Inventors: Brian R. Scott, Mark David Wogulis, Sven Pedersen, James Lavigne
  • XYLANASE VARIANTS AND POLYNUCLEOTIDES ENCODING SAME
    Publication number: 20170096687
    Abstract: The present invention relates to xylanase variants, comprising an alteration at least at one position corresponding to position 87 of the polypeptide of SEQ ID NO: 3, wherein the variant has xylanase activity and has increased xylanase inhibitor tolerance compared to the xylanase of SEQ ID NO: 3; and i) wherein the variant has at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%, but less than 100% sequence identity to the polypeptide of SEQ ID NO: 3; or ii) wherein the number of alterations is 1-20, e.g., 1-10 such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 alterations. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Application
    Filed: June 25, 2015
    Publication date: April 6, 2017
    Applicant: NOVOZYMES A/S
    Inventors: Brian R. Scott, Mark David Wogulis, Sven Pedersen, James Lavigne